Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
antitubercular agents
delamanid
extensively drug-resistant tuberculosis
multidrug-resistant tuberculosis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
11 07 2020
11 07 2020
Historique:
received:
10
07
2019
accepted:
30
10
2019
pubmed:
5
11
2019
medline:
13
3
2021
entrez:
3
11
2019
Statut:
ppublish
Résumé
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
Identifiants
pubmed: 31676905
pii: 5611120
doi: 10.1093/cid/ciz1084
doi:
Substances chimiques
Antitubercular Agents
0
Nitroimidazoles
0
OPC-67683
0
Oxazoles
0
Banques de données
ClinicalTrials.gov
['NCT02754765']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-418Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.